What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?

Liam Hayman, Wajeeh Raza Chaudhry, Victor V. Revin, Nikolai Zhelev, Jean-Christophe Bourdon

Research output: Contribution to journalArticle

Abstract

Introduction: For decades, p53 was researched as a single protein with alterations described as mutants. The discovery of 12 human p53 isoforms expressed from 9 transcripts changed this perception, eloquently explaining the numerous roles p53 plays, including apoptosis, senescence and regeneration. 

Area covered: Here, we summarise the p53 isoforms and their relevance to cancer to establish an understanding and theorise on potential applications of the isoforms in clinical practice. 

Expert commentary: Pertaining to the different expression of isoforms in different tumours, it is concluded that the clinical use of isoforms as prognostic and predictive biomarkers will be different depending on the cell type, the tissue origin of the tumours, the position of the TP53 mutation and the driver-oncogene.

LanguageEnglish
Pages149-159
Number of pages11
JournalExpert Review of Molecular Diagnostics
Volume19
Issue number2
Early online date7 Jan 2019
DOIs
Publication statusPublished - 2019

Fingerprint

Protein Isoforms
Biomarkers
Neoplasms
Oncogenes
Regeneration
Apoptosis
Mutation
Proteins

Cite this

Hayman, Liam ; Chaudhry, Wajeeh Raza ; Revin, Victor V. ; Zhelev, Nikolai ; Bourdon, Jean-Christophe. / What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?. In: Expert Review of Molecular Diagnostics. 2019 ; Vol. 19, No. 2. pp. 149-159.
@article{1754d607877d4abbbac8cc3b4e807d30,
title = "What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?",
abstract = "Introduction: For decades, p53 was researched as a single protein with alterations described as mutants. The discovery of 12 human p53 isoforms expressed from 9 transcripts changed this perception, eloquently explaining the numerous roles p53 plays, including apoptosis, senescence and regeneration. Area covered: Here, we summarise the p53 isoforms and their relevance to cancer to establish an understanding and theorise on potential applications of the isoforms in clinical practice. Expert commentary: Pertaining to the different expression of isoforms in different tumours, it is concluded that the clinical use of isoforms as prognostic and predictive biomarkers will be different depending on the cell type, the tissue origin of the tumours, the position of the TP53 mutation and the driver-oncogene.",
author = "Liam Hayman and Chaudhry, {Wajeeh Raza} and Revin, {Victor V.} and Nikolai Zhelev and Jean-Christophe Bourdon",
year = "2019",
doi = "10.1080/14737159.2019.1563484",
language = "English",
volume = "19",
pages = "149--159",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer? / Hayman, Liam; Chaudhry, Wajeeh Raza; Revin, Victor V.; Zhelev, Nikolai; Bourdon, Jean-Christophe.

In: Expert Review of Molecular Diagnostics, Vol. 19, No. 2, 2019, p. 149-159.

Research output: Contribution to journalArticle

TY - JOUR

T1 - What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?

AU - Hayman, Liam

AU - Chaudhry, Wajeeh Raza

AU - Revin, Victor V.

AU - Zhelev, Nikolai

AU - Bourdon, Jean-Christophe

PY - 2019

Y1 - 2019

N2 - Introduction: For decades, p53 was researched as a single protein with alterations described as mutants. The discovery of 12 human p53 isoforms expressed from 9 transcripts changed this perception, eloquently explaining the numerous roles p53 plays, including apoptosis, senescence and regeneration. Area covered: Here, we summarise the p53 isoforms and their relevance to cancer to establish an understanding and theorise on potential applications of the isoforms in clinical practice. Expert commentary: Pertaining to the different expression of isoforms in different tumours, it is concluded that the clinical use of isoforms as prognostic and predictive biomarkers will be different depending on the cell type, the tissue origin of the tumours, the position of the TP53 mutation and the driver-oncogene.

AB - Introduction: For decades, p53 was researched as a single protein with alterations described as mutants. The discovery of 12 human p53 isoforms expressed from 9 transcripts changed this perception, eloquently explaining the numerous roles p53 plays, including apoptosis, senescence and regeneration. Area covered: Here, we summarise the p53 isoforms and their relevance to cancer to establish an understanding and theorise on potential applications of the isoforms in clinical practice. Expert commentary: Pertaining to the different expression of isoforms in different tumours, it is concluded that the clinical use of isoforms as prognostic and predictive biomarkers will be different depending on the cell type, the tissue origin of the tumours, the position of the TP53 mutation and the driver-oncogene.

U2 - 10.1080/14737159.2019.1563484

DO - 10.1080/14737159.2019.1563484

M3 - Article

VL - 19

SP - 149

EP - 159

JO - Expert Review of Molecular Diagnostics

T2 - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -